• LAST PRICE
    0.8099
  • TODAY'S CHANGE (%)
    Trending Down-0.2801 (-25.6972%)
  • Bid / Lots
    0.8600/ 3
  • Ask / Lots
    0.9500/ 2
  • Open / Previous Close
    1.0600 / 1.0900
  • Day Range
    Low 0.7923
    High 1.0783
  • 52 Week Range
    Low 0.7923
    High 21.4000
  • Volume
    270,670
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.09
TimeVolumeONCO
09:32 ET5031.06
09:33 ET1991.06
09:35 ET20001.06
09:39 ET13441.06
09:51 ET6361.0783
10:00 ET10001.055
10:02 ET20001.0401
10:08 ET10001.03
10:13 ET2551.0362
10:18 ET1001.03
10:20 ET2001.03
10:22 ET18271.05
10:24 ET7871.0508
10:31 ET1001.07
10:36 ET3001.06
10:40 ET1001.05
10:42 ET5191.05
10:44 ET1001.03
10:45 ET8001.05
10:49 ET6001.04
10:51 ET2941.03
10:54 ET21941.03
10:56 ET12001.045
10:58 ET2001.04
11:07 ET23001.03
11:12 ET3141.02
11:14 ET13001.0317
11:16 ET3401.02
11:18 ET2001.03
11:20 ET1001.03
11:21 ET2001.04
11:23 ET21001.06
11:30 ET1001.04
11:32 ET3001.04
11:36 ET1001.03
11:41 ET3001.03
11:43 ET3001.04
11:48 ET1001.03
11:50 ET1001.03
11:52 ET1001.03
11:54 ET1001.03
11:56 ET1001.03
12:03 ET2001.03
12:06 ET2001.03
12:08 ET1001.03
12:10 ET3001.03
12:14 ET1001.03
12:15 ET2001.03
12:17 ET1001.03
12:21 ET3001.0299
12:24 ET4001.02
12:28 ET4001.02
12:30 ET47601.03
12:42 ET19401.02
12:46 ET7281.02
12:48 ET68280.9942
12:50 ET65500.9756
12:51 ET2000.97
12:53 ET2000.972
12:55 ET4000.9588
12:57 ET7000.9601
01:00 ET519000.86
01:02 ET9000.86
01:04 ET9000.86
01:06 ET8000.8982
01:08 ET5000.864201
01:09 ET7000.84
01:11 ET27000.85275
01:13 ET17980.8654
01:15 ET13020.8651
01:18 ET25980.89
01:20 ET45530.895
01:22 ET12630.8651
01:27 ET103190.9098
01:29 ET50480.89
01:31 ET1000.9
01:36 ET2000.9048
01:38 ET3000.8963
01:42 ET2000.8963
01:44 ET2000.89
01:45 ET2000.8963
01:47 ET3000.8963
01:51 ET10580.89
01:58 ET26000.875
02:00 ET4200.89
02:02 ET4500.8837
02:03 ET5000.8986
02:05 ET10000.88269
02:09 ET1000.8827
02:12 ET14750.8864
02:16 ET3600.875
02:18 ET1000.892028
02:21 ET20000.8929
02:25 ET1000.9098
02:27 ET2000.9
02:30 ET2000.88614
02:38 ET3000.8864
02:41 ET29000.8901
02:43 ET2000.8901
02:45 ET2120.8901
02:48 ET25730.8901
02:52 ET29630.89
02:54 ET2440.89
02:56 ET2000.89
02:57 ET1000.89
03:01 ET4250.892899
03:03 ET2000.89
03:10 ET14860.89
03:12 ET2000.8902
03:14 ET1000.8901
03:15 ET9990.8902
03:17 ET3000.8888
03:19 ET5000.8924
03:21 ET1000.8888
03:24 ET2280.8941
03:28 ET34260.893444
03:30 ET20840.9
03:32 ET23590.886
03:33 ET22730.8876
03:35 ET44000.8876
03:37 ET4000.9
03:39 ET5000.8876
03:42 ET4000.8876
03:44 ET3000.8881
03:46 ET27140.8989
03:48 ET4000.8928
03:50 ET9000.89
03:51 ET11000.8824
03:53 ET6000.875
03:55 ET7000.875
03:57 ET31880.8767
04:00 ET330160.8099
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesONCO
Onconetix Inc
9.0M
0.0x
---
United StatesCEOS
CeCors Inc
9.0M
---
---
United StatesCMXCD
StimCell Enegetics Inc
8.9M
-27.4x
---
United StatesEVAX
Evaxion Biotech A/S
8.3M
-0.1x
---
United StatesMBIO
Mustang Bio Inc
9.8M
-0.1x
---
United StatesBIXT
Bioxytran Inc
8.2M
-4.9x
---
As of 2024-11-25

Company Information

Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.

Contact Information

Headquarters
201 E. Fifth Street, Suite 1900CINCINNATI, OH, United States 45202
Phone
513-620-4101
Fax
845-818-3588

Executives

Lead Independent Non-Executive Chairman of the Board
James Sapirstein
Interim Chief Executive Officer, Chief Science Officer
Ralph Schiess
Interim Chief Financial Officer
Karina Fedasz
Chief Strategy Officer
Christian Bruehlmann
Independent Director
Thomas Meier

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$9.0M
Revenue (TTM)
$1.5M
Shares Outstanding
8.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-104.90
Book Value
$105.06
P/E Ratio
0.0x
Price/Sales (TTM)
6.2
Price/Cash Flow (TTM)
---
Operating Margin
-3,533.65%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.